GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | 12-2001 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,109 | -2,698 | -791 | -822 | -3,495 |
| Depreciation Amortization | 154 | 827 | 177 | 282 | 412 |
| Accounts receivable | -26 | 22 | -63 | -39 | 353 |
| Accounts payable and accrued liabilities | -142 | -118 | 288 | -268 | -39 |
| Other Working Capital | -769 | 499 | 291 | -468 | 644 |
| Other Operating Activity | 1,799 | 426 | -131 | 307 | 700 |
| Operating Cash Flow | $-2,093 | $-1,042 | $-229 | $-1,008 | $-1,425 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -33 | -47 | -13 | -6 | -11 |
| Net Acquisitions | -2,808 | N/A | N/A | N/A | N/A |
| Purchase Of Investment | -3,060 | N/A | N/A | N/A | N/A |
| Sale Of Investment | N/A | N/A | 62 | N/A | 19 |
| Purchase Sale Intangibles | -172 | -262 | N/A | N/A | N/A |
| Other Investing Activity | -172 | -262 | -147 | -174 | -164 |
| Investing Cash Flow | $-6,073 | $-309 | $-98 | $-180 | $-156 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 3,060 | 1,686 | N/A | N/A | N/A |
| Debt Repayment | N/A | N/A | N/A | N/A | -212 |
| Common Stock Issued | 285 | 4,006 | 247 | N/A | N/A |
| Other Financing Activity | 748 | 0 | 0 | 1,406 | 0 |
| Financing Cash Flow | $4,093 | $5,692 | $247 | $1,406 | $-212 |
| Exchange Rate Effect | N/A | -26 | 28 | -15 | -45 |
| Beginning Cash Position | 4,687 | 372 | 424 | 221 | 2,059 |
| End Cash Position | 614 | 4,687 | 372 | 424 | 221 |
| Net Cash Flow | $-4,073 | $4,315 | $-52 | $203 | $-1,838 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,093 | -1,042 | -229 | -1,008 | -1,425 |
| Capital Expenditure | -33 | -47 | -13 | -6 | -11 |
| Free Cash Flow | -2,126 | -1,089 | -242 | -1,014 | -1,436 |